Columbia Management Advisors, Inc. CLMB 深滬

等待開盤 10-08 09:30:00 美东时间

137.56

-5.840

-4.07%

華盛通

立即下載

最高144.35
今開144.35
成交量 2.56万股
最低 137.56
昨收 143.40
總市值 6.35亿
52周最高 145.02
市盈率 ^靜 33.84
換手率 0.56%
52周最低 88.56
委比 -60.00%
總股本 461.72万
歷史最高 145.02
量比 0.45
振幅 4.74%
歷史最低 1.37
每手 1
風險率 11.91%

個股概要

財務分析

公司資料

分紅派息

分時圖
日k
周k
月k

相關新聞

Climb Channel Solutions named as one of “America’s Greatest Companies 2025” by Newsweek

Climb Channel Solutions, a global technology distributor, has been named among Newsweek's 2025 America’s Greatest Companies. The ranking evaluates companies based on financial performance, workforce, innovation, and sustainability. Climb is recognized alongside top firms like Oracle, NVIDIA, Amazon, and Microsoft. It also ranks among the top three employers in New Jersey. CEO Dale Foster attributes the achievement to the dedication of its team an...

10-02 12:51
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN

Climb Bio announced positive preclinical CLYM116 data showing reduced IgA and a longer half-life versus first-generation anti-APRIL antibodies. CLYM116's Phase 1 trial starts in Q4 2025, with early results in mid-2026. CLYM116's novel mechanism targets IgA nephropathy, representing a $10-20B market opportunity.

09-29 11:00
美股大行评级 | 潜在涨幅208.48%！HC Wainwright & Co.上调Microbot Medical目标价至12美元，维持"买入"评级

今日重点评级关注：HC Wainwright & Co.：维持Microbot Medical"买入"评级，目标价从9美元升至12美元；Maxim Group：维持Neuphoria Therapeutics"买入"评级，目标价从18美元升至35美元

09-12 12:53
Barrington Research Maintains Outperform on Climb Global Solutions, Maintains $136 Price Target

Barrington Research analyst Vincent Colicchio maintains Climb Global Solutions (NASDAQ:CLMB) with a Outperform and maintains $136 price target.

09-11 20:08
Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025

Climb Bio announces a webcast event on September 29, 2025, featuring its CLYM116 program, a novel anti-APRIL monoclonal antibody targeting IgA nephropathy. The event will include an overview of IgAN, preclinical data comparing CLYM116 to existing treatments, and the company's development strategy. CLYM116 employs a unique 'sweeper' mechanism, potentially offering best-in-class efficacy with less frequent dosing. The webcast will be accessible via...

09-04 11:00
Climb Channel Solutions Announces North American Distribution Partnership with Forcepoint to Deliver Data Security Everywhere

Climb Channel Solutions, a global specialty technology distributor and subsidiary of Climb Global Solutions (NASDAQ: CLMB), has announced a North American distribution partnership with Forcepoint, a global leader in data security. This strategic alliance combines Climb's channel expertise with Forcepoint's AI-native, unified data security platform, enabling organizations to safeguard sensitive information, adapt to changing risks, and support sec...

09-03 11:00
Climb Channel Solutions Partners with Coro to Enhance Cybersecurity Solutions

Climb Channel Solutions, a global technology distributor, partners with Coro to deliver comprehensive cybersecurity solutions, leveraging Coro's unified platform to protect against email threats, endpoint attacks, and data loss. The partnership enhances Climb's cybersecurity portfolio and supports growth for SMBs and distributed enterprises. Both companies aim to simplify cybersecurity delivery for partners, enabling scalable and profitable busin...

08-26 11:00
Climb Bio to Present at Upcoming September 2025 Investor Conferences

Climb Bio, a clinical-stage biotechnology company, announced that its executives will participate in several upcoming investor conferences in New York and virtually. The events include the Cantor Global Healthcare Conference on September 5, the Baird Global Healthcare Conference on September 9, the Morgan Stanley Global Healthcare Conference on September 10, and the Stifel Virtual Immunology and Inflammation Forum on September 10. Live webcasts a...

08-25 11:00
Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Climb Bio reported Q2 2025 financial results, highlighting progress with its lead product budoprutug in clinical trials for immune thrombocytopenia (ITP), systemic lupus erythematosus (SLE), and primary membranous nephropathy (pMN). The company also announced plans to initiate a Phase 2 trial for pMN and a Phase 1 trial for the subcutaneous formulation of budoprutug. CLYM116, targeting IgA nephropathy (IgAN), is advancing toward clinical developm...

08-12 11:00
Why Climb Global Solutions Stock Keeps Climbing?

Climb stock is up over 240% since mid-2023, Adhishthana principles show a classic Phase 9 breakout. Here's what investors need to know next.

07-29 20:17

派息除權日	每股總股息	派息日期
2025-08-11	0.17	2025-08-15
2025-05-12	0.17	2025-05-16
2025-03-17	0.17	2025-03-21
2024-11-08	0.17	2024-11-15
2024-08-16	0.17	2024-08-22
2024-05-10	0.17	2024-05-17
2024-03-08	0.17	2024-03-15
2023-11-10	0.17	2023-11-17
2023-08-11	0.17	2023-08-18
2023-05-12	0.17	2023-05-19
2023-03-10	0.17	2023-03-17
2022-11-10	0.17	2022-11-18
2022-08-12	0.17	2022-08-19
2022-05-13	0.17	2022-05-20
2022-03-11	0.17	2022-03-18
2021-11-12	0.17	2021-11-19
2021-08-13	0.17	2021-08-20
2021-05-14	0.17	2021-05-21
2021-03-11	0.17	2021-03-19
2020-11-20	0.17	2020-11-27
2020-08-21	0.17	2020-08-28
2020-05-15	0.17	2020-05-22
2020-02-28	0.17	2020-03-06
2019-11-15	0.17	2019-11-22
2019-08-16	0.17	2019-08-23
2019-05-17	0.17	2019-05-24
2019-03-06	0.17	2019-03-13
2018-11-09	0.17	2018-11-20
2018-08-10	0.17	2018-08-22
2018-05-11	0.17	2018-05-21
2018-03-02	0.17	2018-03-12
2017-11-09	0.17	2017-11-17
2017-08-09	0.17	2017-08-18
2017-05-08	0.17	2017-05-17
2017-02-14	0.17	2017-02-27
2016-11-04	0.17	2016-11-18
2016-08-04	0.17	2016-08-18
2016-05-06	0.17	2016-05-17
2016-02-11	0.17	2016-02-26
2015-11-06	0.17	2015-11-17
2015-08-06	0.17	2015-08-17
2015-05-11	0.17	2015-05-20
2015-02-13	0.17	2015-02-27
2014-11-06	0.17	2014-11-17
2014-08-04	0.17	2014-08-15
2014-05-02	0.17	2014-05-16
2014-02-13	0.17	2014-02-28
2013-11-01	0.17	2013-11-15
2013-08-02	0.16	2013-08-16
2013-05-03	0.16	2013-05-17
2013-02-08	0.16	2013-02-22
2012-11-02	0.16	2012-11-16
2012-08-03	0.16	2012-08-17
2012-05-03	0.16	2012-05-17
2012-02-06	0.16	2012-02-17
2011-08-05	0.16	2011-08-19
2011-05-05	0.16	2011-05-19
2011-02-07	0.16	2011-02-18
2010-11-05	0.16	2010-11-19
2010-08-10	0.15	2010-08-19
2010-05-10	0.15	2010-05-19
2010-02-10	0.15	2010-02-19
2009-11-10	0.15	2009-11-20
2009-08-11	0.15	2009-08-20
2009-05-11	0.15	2009-05-20
2009-02-11	0.15	2009-02-20
2008-11-12	0.15	2008-11-21
2008-08-05	0.15	2008-08-20
2008-05-05	0.15	2008-05-20
2008-02-05	0.15	2008-02-20
2007-11-02	0.15	2007-11-20
2007-08-02	0.15	2007-08-20
2007-04-30	0.14	2007-05-19
2006-12-28	0.14	2007-01-19
2006-08-31	0.14	2006-09-29
2006-06-28	0.13	2006-07-24
2006-03-30	0.13	2006-04-21
2005-12-29	0.13	2006-01-27
2005-09-28	0.12	2005-10-21
2005-06-29	0.12	2005-07-22
2005-03-31	0.12	2005-04-22
2004-12-31	0.11	2005-01-21
2004-10-01	0.11	2004-10-22
2004-07-01	0.11	2004-07-23
2004-04-01	0.10	2004-04-23
2003-12-31	0.10	2004-01-23
2003-10-02	0.10	2003-10-24
2003-07-02	0.10	2003-07-25
2003-04-03	0.10	2003-04-25

公司名稱	Climb Global Solutions, Inc.
行業分類	Electronics Distributors
業務描述	Climb Global Solutions, Inc. engages in the distribution of software developed by others through resellers indirectly to customers. It operates through the Distribution and Solutions segments. The Distribution segment distributes technical software to corporate resellers, value added resellers (VARs), consultants and systems integrators worldwide under the names Climb Channel Solutions and Sigma Software Distribution. The Solutions segment provides cloud solutions and value-added reseller of software, hardware, and services to customers worldwide under the names TechXtend and Grey Matter. The company was founded by Edwin Huffman Morgens in 1982 and is headquartered in Eatontown, NJ.

Columbia Management Advisors, Inc. CLMB 深 滬

137.56

個股概要

財務分析

公司資料

相關新聞

分紅派息

相關新聞

公司簡介

Columbia Management Advisors, Inc. CLMB 深滬